Ms Tina Abild Olesen is Senior Vice President, Diabetes, at Novo Nordisk A/S and based in Copenhagen, Denmark. She joined the company in 2009, serving in leadership roles in Scandinavia and Germany before moving to headquarters in 2019. As head of the newly created Diabetes unit, she will direct the company’s diabetes strategy and ambition, early planning, access, commercial strategies, launch preparations, and digital solutions.
Prior to joining Novo Nordisk, Ms Olesen worked for GlaxoSmithKline Pharma (formerly Glaxo Wellcome) in Denmark.
Ms Olesen received her Master of Science in Economics & Business Administration from Copenhagen Business School and is a Danish native.